---
document_datetime: 2025-01-20 09:41:33
document_pages: 15
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ocaliva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: ocaliva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 9.221193
conversion_datetime: 2025-12-28 15:13:06.600398
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Ocaliva

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on no   | Summary                                                                                                                                                                                                                             |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10555 /202405  | Periodic Safety Update EU Single assessment - obeticholic acid                                                                                                                                                                                | 16/01/2025 Product                  | n/a                                            | The marketing authorization of Ocaliva was revoked by the Commission Implementing Decision of 30 August 2024. The PRAC concluded that the risk-benefit balance of medicinal products containing obeticholic acid remains unchanged. |
| A20/0045             | Pursuant to Article 20 of Regulation (EC) No 726/2004, the European Commission requested on 12 October 2023 the opinion of the European Medicines Agency further to the results of the study 747-302 showing a potential lack of efficacy and | 29/07/2024                          | 30/08/2024                                     | Please refer to the assessment report in the section 'More information on Ocaliva' - referral: Ocaliva EMEA/H/A-20/1531/C/004093/0045                                                                                               |

Medicinal Product no longer authorised

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | concerning safety profile the CHMP was requested to assess the impact thereof on the benefit-risk balance of Ocaliva and to give its recommendation whether the marketing authorisation of this product should be maintained, varied, suspended or revoked.   |                    |                  | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10555 /202311 | Periodic Safety Update EU Single assessment - obeticholic acid                                                                                                                                                                                                | 13/06/2024         | n/a              | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| N/0048              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                              | 16/04/2024         | 12/07/2024 PL    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| PSUSA/10555 /202305 | Periodic Safety Update EU Single assessment - obeticholic acid                                                                                                                                                                                                | 11/01/2024         | n/a longer       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| N/0046              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                              | 20/12/2023 Product | 12/07/2024 PL no |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| R/0042              | Renewal of the marketing authorisation.                                                                                                                                                                                                                       | 14/09/2023         | 15/11/2023       | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Ocaliva, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| IB/0043             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a Medicinal                                                                                                                                        | 24/08/2023         | n/a              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|                     | re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |                        | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10555 /202211 | Periodic Safety Update EU Single assessment - obeticholic acid                                                                                                                                                                                                                                                                                                                                                                                                                                     | 06/07/2023 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| N/0041              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                   | 08/06/2023 | 15/11/2023 | PL                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0039             | Submission of an updated RMP version 2.0 in order to change to EU Qualified Person for Pharmacovigilance (QPPV), update the list of safety concerns and study data for 747-302 and 747-401. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required Product | 16/03/2023 | n/a no     | longer                 | Reclassification of 'Liver injury' as Important identified risk following variation procedure EMEA/H/C/004093/II/0030 in which section 4.4 of the SmPC was updated to include a new warning on monitoring and management of patients for possible progression of PBC and other hepatic adverse reactions and the adverse events of hepatic failure, blood bilirubin increased, jaundice, and hepatic cirrhosis with the frequency unknown were added as adverse reactions to section 4.8 of the SmPC in the system organ class (SOC) Hepatobiliary disorders. Removal of Missing information 'Use in patients with moderate to severe hepatic impairment following the update of section 4.3 of the SmPC in the same variation procedure that included a contraindication in patients with decompensated cirrhosis (e.g., Child-Pugh Class B or C) or a prior decompensation event. |
| PSUSA/10555 /202205 | Periodic Safety Update EU Single assessment - obeticholic acid Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                           | 12/01/2023 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| T/0037              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 07/11/2022 | 16/12/2022 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| R/0034   | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 15/09/2022   | 09/11/2022    |                                  | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Ocaliva, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. authorised                                                                                                                                                                                                                                                                                                                                                                                                         |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0035  | B.I.a.1.g - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new manufacturer of the AS that is not supported by an ASMF and requires significant update to the relevant AS section in the dossier                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 15/09/2022   | n/a           | longer                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0030  | Update of section 4.3 of the SmPC in order to include a contraindication in patients with decompensated cirrhosis (e.g., Child-Pugh Class B or C) or a prior decompensation event based on interim analyses from the ongoing studies 747-302 and 747-401 listed as Specific Obligations in Annex II and on post marketing data. Consequently, dosing instructions for patients with CP-B and CP-C cirrhosis were removed from Section 4.2, and the wording in sections 4.2, 4.4 and 5.2 of the SmPC have been updated accordingly. In addition, section 4.4 of the SmPC has been updated to include a new warning on monitoring and management of patients for possible progression of PBC and other hepatic adverse reactions. Furthermore, the adverse events of hepatic failure, Medicinal Product | 19/05/2022   | 24/06/2022 no | SmPC, Annex II, Labelling and PL | During a pre-planned unblinded interim analysis (IA) that took place in September 2020 for studies 747-401 and 747-302 that both enrolled primary biliary cholangitis (PBC) population including patients with decompensated cirrhosis, the independent data monitoring committee (DMC) determined in their blinded report that it does not appear to be feasible to establish the safety and efficacy of Ocaliva in this patient population. Further, whilst stronger evidence from the well-controlled blinded clinical trials indicates no difference in the occurrence of decompensation events in Ocaliva vs placebo, post-marketing data suggest an association between hepatic events and PBC patients taking Ocaliva, particularly in cirrhosis patients (CP-B and C). It was acknowledged by the CHMP that reporting rates observed in post-market data are still lower than the background |

<div style=\"page-break-after: always\"></div>

blood bilirubin increased, jaundice, and hepatic cirrhosis with the frequency unknown were added to section 4.8 of the SmPC in the system organ class (SOC) Hepatobiliary disorders.

The MAH has also taken the opportunity to remove the outdated term 'primary biliary cirrhosis' from section 4.1 and to make editorial changes to sections 4.9, 5.1 and Annex IIE to improve clarity and correct typographical errors. The Package Leaflet is updated accordingly.

Also, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.2.

C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data rates observed in PBC cohorts in epidemiologic studies but considering that it will no longer be feasible to establish the safety and efficacy of Ocaliva in this patient population, the CHMP agreed to add a contraindication in patients with decompensated cirrhosis (e.g. Child-Pugh Class B or C) or prior decompensation event. Further, post-marketing research revealed an increased risk in patients with concomitant liver disease e.g. autoimmune hepatitis and alcoholic liver disease. Accordingly, section 4.4 of the SmPC emphasizes now that patients with an increased risk of hepatic decompensation should be closely monitored. in total 45.2% of the 186 post-marketing cases of hepatic adverse events could not be classified to a CP class and of them 14.3% were described in patients presumed to be non-cirrhotic; considering the contraindication in case of progression and the risk of hepatic decompensation all patients should be routinely (i.e. not only at treatment initiation) monitored for progression of PBC including hepatic adverse reaction with laboratory and clinical assessments if treatment needs to be discontinued as now reflected in Section 4.4. of the SmPC.

For more information, please refer to the Summary of Product Characteristics.

| IB/0033             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data   | 26/01/2022   | n/a   |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| PSUSA/10555 /202105 | Periodic Safety Update EU Single assessment - obeticholic acid                                                                                                           | 13/01/2022   | n/a   | PRAC Recommendation - maintenance |

Medicinal Product no longer authorised

<div style=\"page-break-after: always\"></div>

| R/0027   | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 11/11/2021   | 12/01/2022           | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for OCALIVA, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0029  | Update of sections 4.2 and 5.2 of the Summary of Product Characteristics (SmPC) in order to clarify information on posology recommendations in renally impaired patients and add information on pharmacokinetic properties following the results from Study 474-120 (a Phase I, Open-Label Study to Investigate the Effect of Renal Impairment on the Single-Dose Pharmacokinetics of Obeticholic Acid). Editorial changes have also been made to the Section 4.5. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data Medicinal Product | 11/11/2021   | 12/01/2022 no longer | SmPC Study 474-120 (a Phase I, Open-Label Study to Investigate the Effect of Renal Impairment on the Single-Dose Pharmacokinetics using 25 mg of Obeticholic Acid) revealed results in plasma exposures to the active substance and its conjugates increased by approximately 1.4 to 1.6 fold in subjects with mild (modification of diet in renal disease [MDRD] eGFR ≥ 60 and < 90 mL/min/1.73 m2), moderate (MDRD eGFR ≥ 30 and < 60 mL/min/1.73 m2) and severe (MDRD eGFR ≥ 15 and < 30 mL/min/1.73 m2) renal impairment compared to subjects with normal renal function. This modest increase is not considered to be clinically meaningful. Therefore, information on posology recommendation in section 4.2 of the Summary of product Characteristics is proposed to confirm current recommendation that no dose adjustment is required in renally impaired patients. Furthermore, section 5.2 is updated to add information on pharmacokinetic properties following the study's results. Editorial changes have also been made to Section 4.5. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| II/0026             | Update of the RMP to version 1.3 (dated of 11 June 2021) in order to update the format in accordance with template to EMA/164014/2018 Rev.2.0.1 and to add Specific Obligation clinical studies 747-302 and 747-401 to part IV. Plans for post-authorisation efficacy studies of the RMP. This change has been agreed by the CHMP in the outcome Ocaliva 2020 Annual Renewal (EMEA/H/C/004093/R/0023). Other changes also include an update to the exposure data from clinical studies and addition of data on post-marketing experience up to the DLP (26 May 2020) and addition of some specific relevant SmPC wording in the risk minimisation measures. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH Product   | 30/09/2021   | n/a no longer   | The RMP update (version 1.3, dated 11 June 2021) was approved and reflects the implementation of the following changes: • Update RMP in accordance with template EMA/164014/2018 Rev.2.0.1. • Specific Obligation clinical studies 747-302 and 747-401 have been added to part IV. Plans for post-authorisation efficacy studies of the RMP and the due dates of Studies 747-302 and 747-401 updated to Dec 2023. • Data on post-marketing experience up to the DLP of PBRER #6 (26 May 2020) have been added. • Exposure data from clinical studies up to DLP of 26 Oct 2018 have been added. • Specific relevant SmPC wording have been included where applicable in the Risk Minimisation Measure. • Change to EU Qualified Person for Pharmacovigilance (QPPV). • The important identified risk of pruritus was removed. authorised   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0031             | B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 20/08/2021   | n/a             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| PSUSA/10555 /202005 | Periodic Safety Update EU Single assessment - obeticholic acid                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 14/01/2021   | n/a             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| R/0023              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 12/11/2020   | 11/01/2021      | SmPC, Annex Labelling The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | and PL                                                | having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Ocaliva, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. Despite additional measures implemented and aimed at increasing recruitment, the submission due date of the CSR of Study 747-401 is postponed to 2023 due to COVID related patient enrolment difficulties. In addition, the MAH took the opportunity to bring the PI in line with the last QRD template (version 10.1). authorised   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0025/G | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site Medicinal Product | 16/11/2020 18/11/2021 SmPC, Annex II and PL no longer |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| R/0018      | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 27/02/2020 28/04/2020                                 | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            | medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for OCALIVA, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. authorised   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0022             | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                              | 30/01/2020 | n/a                                                                                                                                                                                                                                                        |
| IB/0021             | B.II.c.z - Change in control of excipients in the Finished Product - Other variation                                                                                                                                                                                                                                                                                                                                                                                             | 24/01/2020 | n/a longer                                                                                                                                                                                                                                                 |
| PSUSA/10555 /201905 | Periodic Safety Update EU Single assessment - obeticholic acid                                                                                                                                                                                                                                                                                                                                                                                                                   | 16/01/2020 | n/a PRAC Recommendation - maintenance no                                                                                                                                                                                                                   |
| IA/0020/G           | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place Product | 19/12/2019 | n/a n/a                                                                                                                                                                                                                                                    |
| II/0016/G           | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Medicinal                                                                                                                                                                                                                                                                                                                | 12/09/2019 |                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of obsolete parameter)                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |                                                       | an       |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------------------------------------------------|----------|
| PSUSA/10555 /201811 | Periodic Safety Update EU Single assessment - obeticholic acid                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 14/06/2019 | n/a authorised                                        |          |
| N/0017              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 06/06/2019 | 11/02/2020 PL                                         |          |
| IAIN/0015           | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 22/03/2019 | 11/02/2020 SmPC, Labelling and                        |          |
| IAIN/0013/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure Medicinal Product | 08/02/2019 | PL 11/02/2020 Annex II and PL Labelling and no longer |          |
| T/0012              | of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 11/12/2018 | 23/01/2019 SmPC,                                      | Transfer |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |               | PL          |                                                                                                                                            |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10555 /201805 | Periodic Safety Update EU Single assessment - obeticholic acid                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 17/01/2019 | n/a           |             | PRAC Recommendation - maintenance authorised                                                                                               |
| R/0009              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 18/10/2018 | 12/12/2018    |             |                                                                                                                                            |
| IB/0011             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 17/10/2018 | 12/12/2018    | SmPC        |                                                                                                                                            |
| PSUSA/10555 /201712 | Periodic Safety Update EU Single assessment - obeticholic acid                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 12/07/2018 | n/a           | longer      | PRAC Recommendation - maintenance                                                                                                          |
| PSUSA/10555 /201706 | Periodic Safety Update EU Single assessment - obeticholic acid                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 25/01/2018 | 21/03/2018 no | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10555/201706. |
| IB/0007/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for Medicinal Product | 15/03/2018 | n/a           |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | batch control/testing takes place B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation   |            | longer     | authorised                                                                                                                                                                                                                          |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0006/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate Medicinal Product     | 09/01/2018 | n/a no     |                                                                                                                                                                                                                                     |
| R/0002    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 12/10/2017 | 01/12/2017 | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            | medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for OCALIVA, subject to the Specific Obligations and Conditions as laid down in Annex to the Opinion. authorised   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0005   | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 24/10/2017 | n/a                                                                                                                                                                                                                                                     |
| IA/0003/G | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 01/08/2017 | n/a no longer                                                                                                                                                                                                                                           |
| IB/0001/G | This was an application for a group of variations. B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside Medicinal Product | 21/04/2017 | 01/12/2017 SmPC, Labelling and PL                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->